To observe the effect on total liver volume ( TLV ) on and off therapy in selected symptomatic patients with autosomal dominant polycystic kidney disease ( ADPKD ) or autosomal dominant polycystic liver disease ( PLD ) who received octreotide long-acting release ( OctLAR ) for up to 4 years .